Skip to content
星期一, 8 八月, 2022
Latest:
智慧財產
媒體新聞
獲獎實績
學術發表
長弘生物科技股份有限公司
研發抗癌藥物的明日之星
關於長弘
創辦人的話
產品研發
智慧財產
最新消息
聯絡我們
EN
Local delivery therapy of Cerebraca® Wafer being highlighted in the natural review
←
Case report – Cerebraca® Wafer implantation combined with CIK therapy for the treatment of recurrent Glioblastoma revealed superior clinical outcome (overall survival extended for more than 24 months).